External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort

Pompe, 2018, Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence, Prostate, 78, 676, 10.1002/pros.23511 Pound, 1999, Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, 1591, 10.1001/jama.281.17.1591 Freedland, 2005, Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy, JAMA, 294, 433, 10.1001/jama.294.4.433 Van den Broeck, 2019, Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review, Eur Urol, 75, 967, 10.1016/j.eururo.2018.10.011 Kaplan, 1958, Nonparametrici estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Scrucca, 2010, Regression modeling of competing risk using R: an in depth guide for clinicians, Bone Marrow Transpl, 45, 1388, 10.1038/bmt.2009.359 Lévesque, 2010, Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes, BMJ, 340, 5087, 10.1136/bmj.b5087 Therneau, 2013, Using time dependent covariates and time dependent coefficients in the Cox model, Mayo Clinic Heagerty, 2000, Time-dependent ROC curves for censored survival data and diagnostic marker, Biometrics, 56, 337, 10.1111/j.0006-341X.2000.00337.x Epstein, 2016, A contemporary prostate cancer grading system: a validated alternative to the Gleason score, Eur Urol, 69, 428, 10.1016/j.eururo.2015.06.046 Pompe, 2017, Population-based validation of the 2014 ISUP Gleason grade groups in patients treated with radical prostatectomy, brachytherapy, external beam radiation or no local treatment, Prostate, 77, 686, 10.1002/pros.23316